Mural Oncology plc (MURA) details director option cancellation after $2.035 deal

Rhea-AI Filing Summary

Mural Oncology plc director George Golumbeski reported the cancellation of two stock option grants in connection with the company’s acquisition by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty Corporation. The transaction transferred all issued and to‑be‑issued Mural shares for a cash purchase price of $2.035 per share, completed on December 5, 2025.

At closing, 8,637 options with a $2.56 exercise price and 15,334 options with a $3.38 exercise price, each for ordinary shares, were canceled and ceased to be outstanding. Under the agreement, options with exercise prices equal to or greater than the $2.035 per share consideration received no cash payment when they were canceled.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Golumbeski George

(Last) (First) (Middle)

C/O MURAL ONCOLOGY PLC

10 EARLSFORT TERRACE

(Street)

DUBLIN 2 L2 D02 T380

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mural Oncology plc [ MURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.56	12/05/2025		D			8,637	(1)(2)	06/10/2035	Ordinary Shares	8,637	(2)	0	D
Stock Option (right to buy)	$3.38	12/05/2025		D			15,334	(2)	07/29/2034	Ordinary Shares	15,334	(2)	0	D

Explanation of Responses:

1. This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time").

2. Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.

	/s/ George Golumbeski	12/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction involving Mural Oncology plc (MURA) is reported here?

The report shows that director George Golumbeski had two grants of stock options on Mural Oncology ordinary shares canceled in connection with the company’s acquisition by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty Corporation.

What were the terms of the Mural Oncology (MURA) acquisition linked to this option cancellation?

Under a Transaction Agreement dated August 20, 2025, XRA 5 Corp. acquired all issued and to‑be‑issued share capital of Mural Oncology for a cash purchase price of $2.035 per share, with the acquisition completed on December 5, 2025.

How many Mural Oncology (MURA) stock options were canceled for the director, and at what exercise prices?

On December 5, 2025, 8,637 stock options with a $2.56 exercise price and 15,334 stock options with a $3.38 exercise price, each over ordinary shares, were canceled, leaving 0 derivative securities beneficially owned.

Why were these Mural Oncology (MURA) options canceled without payment?

The Transaction Agreement states that at the effective time, each option with an exercise price per share equal to or greater than the $2.035 per share scheme consideration was canceled and ceased to be outstanding, and no cash consideration was delivered in exchange for such options.

Who is the reporting person in this Mural Oncology (MURA) insider report and what is their role?

The reporting person is George Golumbeski, who is identified as a director of Mural Oncology plc and files individually as one reporting person.

What types of securities underlay the canceled Mural Oncology (MURA) stock options?

Both canceled derivative positions were stock options (right to buy), each exercisable for Mural Oncology ordinary shares, in amounts of 8,637 and 15,334 underlying shares respectively.